Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
32
datasets available to search
ShareScore release 0.9.0
Dataset results
32 results for “patent foramen ovale closure”
GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
ClinicalTrials.gov study NCT00738894. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial
ClinicalTrials.gov study NCT00465270. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Patent Foramen Ovale Closure in Older Patients
ClinicalTrials.gov study NCT04780022. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia
ClinicalTrials.gov study NCT05213104. IPD Sharing: NO. Countries: 1. Publications: 2.
Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale (DEFENSE-PFO)
ClinicalTrials.gov study NCT01550588. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study
ClinicalTrials.gov study NCT04926142. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine
ClinicalTrials.gov study NCT02127294. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea
ClinicalTrials.gov study NCT01780207. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)
ClinicalTrials.gov study NCT00201461. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure
ClinicalTrials.gov study NCT05907694. IPD Sharing: NO. Countries: 1. Publications: 37.
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
ClinicalTrials.gov study NCT00562289. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Data from: Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence
Objective: To examine the relative impact of three management options in patients less than 60 years old with cryptogenic stroke and a patent foramen ovale (PFO): PFO closure plus antiplatelet therapy, antiplatelet therapy alone, and anticoagulation alone. Design: Systematic review and network meta-analysis (NMA) supported by complementary external evidence Data sources: Medline, EMBASE, and Cochrane CENTRAL. Study selection: Randomised controlled trials (RCTs) addressing PFO closure and/or medical therapies in patients with PFO and cryptogenic stroke. Review methods: We conducted an NMA complemented with external evidence and rated certainty of evidence using the GRADE system. Results: Ten RCTs in eight studies proved eligible (n=4416). PFO closure versus antiplatelet therapy probably results in substantial reduction in ischaemic stroke recurrence (risk difference per 1000 patients over 5 years [RD]: -87, 95% credible interval [CrI] -100 to -33; moderate certainty). Compared with anticoagulation, PFO closure may confer little or no difference in ischaemic stroke recurrence (low certainty) but probably has a lower risk of major bleeding (RD -20, 95% Crl -27 to -2, moderate certainty). Relative to either medical therapy, PFO closure probably increases the risk of persistent atrial fibrillation (RD 18, CI +5 to +56, moderate certainty) and device-related adverse events (RD +36, 95% CI +23 to +50, high certainty). Anticoagulation, compared to antiplatelet therapy, may reduce the risk of ischaemic stroke recurrence (RD -71, 95% CrI -100 to +17, low certainty), but probably increases the risk of major bleeding (RD +12, CrI -5 to +65, moderate certainty). Conclusions: In patients less than 60 years old, PFO closure probably confers an important reduction in ischaemic stroke recurrence compared to antiplatelet therapy alone but may make no difference compared to anticoagulation. PFO closure incurs a risk of persistent atrial fibrillation and device-related adverse events. Compared to alternatives, anticoagulation probably increases major bleeding.
Procedural Success and Safety of the Nit-Occlud® Patent Foramen Ovale (PFO) Closure Device and Its Application System
ClinicalTrials.gov study NCT00968032. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Data from: Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence
Open the record for dataset details and reuse information.
The PROOF Trial - Prospective, Open-label, Multicenter, Non-randomized Investigation on Percutaneous Patent Foramen Ovale (PFO) Closure Using the Occlutech PFO Occluder to Prevent Recurrence of Stroke
ClinicalTrials.gov study NCT04029233. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Prospective Clinical Follow-up After the Percutaneous Closure of a Patent Foramen Ovale
ClinicalTrials.gov study NCT01149447. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation
ClinicalTrials.gov study NCT03232450. IPD Sharing: NO. Countries: 1. Publications: 0.
Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study
ClinicalTrials.gov study NCT04881578. IPD Sharing: NO. Countries: 1. Publications: 0.
Timing of Closure of Patent Foramen Ovale Following Birth
ClinicalTrials.gov study NCT01032785. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Does Patent Foramen Ovale Closure Improve Exercise Capacity & Prevent Blood Flow Through Intrapulmonary Shunt
ClinicalTrials.gov study NCT03904290. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.